There is provided an active compound comprising bicarbonate of soda and/or magnesium carbonate for use in the treatment of a viral infection. As the pH of the host increases through administration of this pharmaceutical composition or preparation there may be a reduction in the ability of viral cells to fuse with the host cells. In any event, it has been found that administration of such a composition treats a viral infection or can act as a prophylaxis. The active compound may comprise only bicarbonate of soda (sodium bicarbonate), only magnesium carbonate or a mixture of bicarbonate of soda and magnesium carbonate.

There is provided an active compound comprising bicarbonate of soda and/or magnesium carbonate for use in the treatment of a viral infection. As the pH of the host increases through administration of this pharmaceutical composition or preparation there may be a reduction in the ability of viral cells to fuse with the host cells. In any event, it has been found that administration of such a composition treats a viral infection or can act as a prophylaxis. The active compound may comprise only bicarbonate of soda (sodium bicarbonate), only magnesium carbonate or a mixture of bicarbonate of soda and magnesium carbonate.

Compositions that comprise salts, compounds and complexes of .sup.64Zn-enriched zinc, such as .sup.64Zn-enriched zinc aspartate, and further optionally include .sup.85Rb-enriched rubidium salt compounds of general formula 1, below, wherein each of R.sub.1 through R.sub.14 is independently selected from H, OH, F, Cl, Br, I, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, and NO.sub.2, such as the compound of Formula 1 in which R.sub.3 is CH.sub.3 and all other R groups are H for use to treat a neurodegenerative disease (NDD), such as Parkinson's disease (PD). Methods that entail administering such compositions to treat an NDD, such as PD, optionally in combination with any other treatment for an NDD such as for PD.

##STR00001##

Compositions that comprise salts, compounds and complexes of .sup.64Zn-enriched zinc, such as .sup.64Zn-enriched zinc aspartate, and further optionally include .sup.85Rb-enriched rubidium salt compounds of general formula 1, below, wherein each of R.sub.1 through R.sub.14 is independently selected from H, OH, F, Cl, Br, I, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, and NO.sub.2, such as the compound of Formula 1 in which R.sub.3 is CH.sub.3 and all other R groups are H for use to treat a neurodegenerative disease (NDD), such as Parkinson's disease (PD). Methods that entail administering such compositions to treat an NDD, such as PD, optionally in combination with any other treatment for an NDD such as for PD.

##STR00001##

Described is an initial liquid composition with at least antimicrobial, antibacterial, and/or anti-viral properties comprising chelated metal oxide particles suspended in a polyol, such that metal oxide particles are homogeneously dispersed in a primarily liquid based polyol carrier so that chelated metal oxide particles form a stable complex suspension that is optionally an alkaline based aqueous silver oxide dispersion. The liquid composition can be subsequently added to any polymer or polymer compound/system where the polymer degrades or melts at a temperature lower than the polyol carrier degradation or boiling temperature. The metal oxide complex may also impart beneficial semi-conductive or conductive as well as permeability and flammability property changes to the polymer (host) system.

Described is an initial liquid composition with at least antimicrobial, antibacterial, and/or anti-viral properties comprising chelated metal oxide particles suspended in a polyol, such that metal oxide particles are homogeneously dispersed in a primarily liquid based polyol carrier so that chelated metal oxide particles form a stable complex suspension that is optionally an alkaline based aqueous silver oxide dispersion. The liquid composition can be subsequently added to any polymer or polymer compound/system where the polymer degrades or melts at a temperature lower than the polyol carrier degradation or boiling temperature. The metal oxide complex may also impart beneficial semi-conductive or conductive as well as permeability and flammability property changes to the polymer (host) system.

The present invention provides food products, nutritional programs, and methods for meeting nutritional needs of subjects with dementia and related cognitive disorders. In one embodiment, the invention provides a food product comprising a reversibly sealed container and a soup, wherein the soup is in the container and comprises a total volume of 200-2000 mls, a vegetable or meat component, 300 to 2500 calories, a macronutrient caloric distribution comprising: 20-80% fat, 10-45% protein, and 10-65% carbohydrate, about 2% to about 40% medium chain triglycerides, omega 3 fatty acids in an amount of 100 to 2000 mg and less than 20 solid food particles having a volume greater than about 20 cm.sup.3. Such food products, when administered to affected subjects, can positively impact (i) nutritional status; (ii) quality of life; (iii) disease course; (v) the demand for assistance from a care giver; (vi) subject compliance with a nutritional plan using the food product, and (vii) ease of monitoring compliance by the caregiver for verification.

The present invention provides food products, nutritional programs, and methods for meeting nutritional needs of subjects with dementia and related cognitive disorders. In one embodiment, the invention provides a food product comprising a reversibly sealed container and a soup, wherein the soup is in the container and comprises a total volume of 200-2000 mls, a vegetable or meat component, 300 to 2500 calories, a macronutrient caloric distribution comprising: 20-80% fat, 10-45% protein, and 10-65% carbohydrate, about 2% to about 40% medium chain triglycerides, omega 3 fatty acids in an amount of 100 to 2000 mg and less than 20 solid food particles having a volume greater than about 20 cm.sup.3. Such food products, when administered to affected subjects, can positively impact (i) nutritional status; (ii) quality of life; (iii) disease course; (v) the demand for assistance from a care giver; (vi) subject compliance with a nutritional plan using the food product, and (vii) ease of monitoring compliance by the caregiver for verification.

The present invention provides food products, nutritional programs, and methods for meeting nutritional needs of subjects with dementia and related cognitive disorders. In one embodiment, the invention provides a food product comprising a reversibly sealed container and a soup, wherein the soup is in the container and comprises a total volume of 200-2000 mls, a vegetable or meat component, 300 to 2500 calories, a macronutrient caloric distribution comprising: 20-80% fat, 10-45% protein, and 10-65% carbohydrate, about 2% to about 40% medium chain triglycerides, omega 3 fatty acids in an amount of 100 to 2000 mg and less than 20 solid food particles having a volume greater than about 20 cm.sup.3. Such food products, when administered to affected subjects, can positively impact (i) nutritional status; (ii) quality of life; (iii) disease course; (v) the demand for assistance from a care giver; (vi) subject compliance with a nutritional plan using the food product, and (vii) ease of monitoring compliance by the caregiver for verification.

The invention relates to the field of medicine, and more particularly to emergency medical assistance. A respiratory intervention is performed on a patient with an artificial gas-air mixture having an increased content of argon of at least 30 vol %, enabling this artificial gas-air mixture to be effective continuously throughout the procedure. Furthermore, the respiratory gaseous medium has an increased content of oxygen with xenon being added and has the following composition: 1-10 vol % of xenon; 30-35 vol % of argon; 60-65 vol % of oxygen. The intervention on the patient with the artificial gas-air mixture of the composition mentioned is performed for 20-40 minutes or more, until specialized medical assistance is given. The method makes it possible to increase the effectiveness, safety and rapidity of relieving acute cerebral and cardiac ischemia, and to reduce the risk of developing an acute cerebral stroke or myocardial infarction.